Abstract
Type 2 diabetes mellitus (DM2) is a chronic condition characterized by progressive hyperglycemia resulting from beta-cell dysfunction and impaired insulin secretion. The maintenance of the target blood glucose level not only promotes preservation of the beta-cell pool but also reduces the risk of the development and progression of vascular complications of diabetes. This paper is designed to report the results of comparative investigations of the application of sulphonylurea derivatives for the treatment of the patients with type 2 diabetes mellitus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
